Hochman JH[au] - Search Results

Year	Number of Results
1981	1
1982	1
1988	1
1991	1
1992	1
1994	2
1996	3
2000	3
2001	2
2002	1
2003	1
2004	2
2005	1
2006	3
2007	3
2008	1
2009	2
2011	1
2014	1
2020	1
2021	1

1

Adapting ADME and Pharmacokinetic Analysis to the Next Generation of Therapeutic Modalities.

Hochman JH. Hochman JH. J Pharm Sci. 2021 Jan;110(1):35-41. doi: 10.1016/j.xphs.2020.09.057. Epub 2020 Oct 10. J Pharm Sci. 2021. PMID: 33049260

2

Cultured rat hepatocytes.

LeCluyse EL, Bullock PL, Parkinson A, Hochman JH. LeCluyse EL, et al. Among authors: hochman jh. Pharm Biotechnol. 1996;8:121-59. doi: 10.1007/978-1-4899-1863-5_9. Pharm Biotechnol. 1996. PMID: 8791809 Review. No abstract available.

3

Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.

Hochman JH, Yamazaki M, Ohe T, Lin JH. Hochman JH, et al. Curr Drug Metab. 2002 Jun;3(3):257-73. doi: 10.2174/1389200023337559. Curr Drug Metab. 2002. PMID: 12083320 Review.

4

RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice.

Wei J, Jones J, Kang J, Card A, Krimm M, Hancock P, Pei Y, Ason B, Payson E, Dubinina N, Cancilla M, Stroh M, Burchard J, Sachs AB, Hochman JH, Flanagan WM, Kuklin NA. Wei J, et al. Among authors: hochman jh. Mol Pharmacol. 2011 Jun;79(6):953-63. doi: 10.1124/mol.110.070409. Epub 2011 Mar 22. Mol Pharmacol. 2011. PMID: 21427169

5

siRNA-mediated knockdown of P450 oxidoreductase in rats: a tool to reduce metabolism by CYPs and increase exposure of high clearance compounds.

Burke RS, Somasuntharam I, Rearden P, Brown D, Deshmukh SV, DiPietro MA, DiMuzio J, Eisenhandler R, Fauty SE, Gibson C, Gindy ME, Hamilton KA, Knemeyer I, Koeplinger KA, Kwon HW, Lifsted TQ, Menzel K, Patel M, Pudvah N, Rudd DJ, Seitzer J, Strapps WR, Prueksaritanont T, Thompson CD, Hochman JH, Carr BA. Burke RS, et al. Among authors: hochman jh. Pharm Res. 2014 Dec;31(12):3445-60. doi: 10.1007/s11095-014-1433-0. Epub 2014 Jul 1. Pharm Res. 2014. PMID: 24980206

6

Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.

Tang C, Kuo Y, Pudvah NT, Ellis JD, Michener MS, Egbertson M, Graham SL, Cook JJ, Hochman JH, Prueksaritanont T. Tang C, et al. Among authors: hochman jh. Biochem Pharmacol. 2009 Sep 15;78(6):642-7. doi: 10.1016/j.bcp.2009.05.026. Epub 2009 May 27. Biochem Pharmacol. 2009. PMID: 19481060

7

Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.

Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T. Hochman JH, et al. Pharm Res. 2004 Sep;21(9):1686-91. doi: 10.1023/b:pham.0000041466.84653.8c. Pharm Res. 2004. PMID: 15497697

8

Renal elimination of a novel and potent alphavbeta3 integrin antagonist in animals.

Prueksaritanont T, Hochman JH, Meng Y, Pudvah NT, Barrish A, Ma B, Yamazaki M, Fernandez-Metzler C, Lin JH. Prueksaritanont T, et al. Among authors: hochman jh. Xenobiotica. 2004 Nov-Dec;34(11-12):1059-74. doi: 10.1080/00498250400015277. Xenobiotica. 2004. PMID: 15801548

9

Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.

Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. Yamazaki M, et al. Among authors: hochman jh. Xenobiotica. 2005 Jul;35(7):737-53. doi: 10.1080/00498250500136676. Xenobiotica. 2005. PMID: 16316932

10

In vitro and in vivo analysis of the mechanism of absorption enhancement by palmitoylcarnitine.

Hochman JH, Fix JA, LeCluyse EL. Hochman JH, et al. J Pharmacol Exp Ther. 1994 May;269(2):813-22. J Pharmacol Exp Ther. 1994. PMID: 8182550

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results